India Pharma Outlook Team | Monday, 23 February 2026
Morepen Laboratories has secured a multi-year CDMO deal worth about INR 825 crore from a global pharmaceutical company, marking one of the largest single contracts in its history.
The announcement was made through a filing with the BSE. The company did not disclose the name of the global pharma client or share additional details about the agreement.
Supplies under the contract are expected to begin within the next four to five months. Execution of the project will continue through the first quarter of financial year 2026-27 (Q1FY27). The CDMO deal is seen as a major step in strengthening Morepen’s position in contract development and manufacturing services.
Also Read: Advancing Interventional Radiology in India Through Collaboration
“This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programs,” said Sushil Suri, chairman and managing director of Morepen.
“We view CDMO as a natural extension of our established active pharmaceutical ingredient (API) strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses,” he added.
For the third quarter of FY26, Morepen reported a 3 percent rise in consolidated net profit to INR 27.5 crore, while revenue increased 6.9 percent to INR 484.16 crore. Shares of Morepen Laboratories were trading 14 percent higher at INR 44.87 on the BSE at 10:20 am following the announcement.
